Clinical Trials Logo

Abdominal Distention clinical trials

View clinical trials related to Abdominal Distention.

Filter by:
  • None
  • Page 1

NCT ID: NCT06285734 Not yet recruiting - Clinical trials for Abdominal Distention

Clinical Characteristics of Small Intestinal Bacterial Overgrowth in Individuals With Abdominal Distention

Start date: March 1, 2024
Phase:
Study type: Observational

Abdominal distention represents a prevalent clinical manifestation characterized by an unclear etiology and pathogenesis. This symptomatology is frequently observed in various conditions, including small intestinal bacterial overgrowth (SIBO) and abnormal orocecal transit time (OCTT). The utilization of the breath test as a non-invasive diagnostic approach has become widespread in recent years for identifying SIBO and abnormalities in OCTT. In this study, the prevalence of SIBO and OCTT irregularities in individuals presenting with abdominal distention was ascertained through the implementation of the breath test. Furthermore, the correlation between abdominal distention and SIBO/OCTT was analysed to enhance the elucidation of the underlying etiology of abdominal distention. These findings aim to offer valuable insights for refining clinical comprehension and strategies related to the diagnosis and treatment of abdominal distention.

NCT ID: NCT06154928 Completed - Clinical trials for Laparoscopic Cholecystectomy

Effects of Warm Water on GI System in Laparoscopic Cholecystectomy Patients

LCSS
Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Objective: The study was carried out to determine the effect of drinking warm water on GIS functions in patients who underwent laparoscopic cholecystectomy surgery.

NCT ID: NCT00331201 Completed - Feeding Intolerance Clinical Trials

SAFEstart Feeding Intolerance Study Phase II

Start date: July 2005
Phase: Phase 2
Study type: Interventional

Feeding intolerance is a common problem in the NICU. Feeding intolerance complicates the hospitalization, lengthens the hospital stay, and adds substantially to the cost of care. We developed a method aimed at treating intestinal villous atrophy. We accomplished preclinical testing of the product, and four Phase I clinical trials, including two at McKay-Dee Hospital in 2004. Our preparation is a sterile, isotonic, solution that simulates human amniotic fluid in electrolyte composition, albumin concentration, and two enterocyte growth factors that are present in human amniotic fluid; erythropoietin and granulocyte colony-stimulating factor. We termed the product SAFEstart, using the acronym Simulated Amniotic Fluid for Enteral administration. This trial on the efficacy and safety of SAFEstart administration as a treatment for neonates who have feeding intolerance. Hypothesis is that infants with feeding intolerance, randomized to the SAFEstart will have a greater enteral calories per kilogram per day for the seven days following conclusion of the SAFEstart administration.